Bank Of Montreal Coherus Bio Sciences, Inc. Transaction History

Bank Of Montreal

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 13, 2024	BUY	$5.89 - $10.52 $72,111 - $128,796	12,243 New	12,243 $83,000
Q2 2022 Aug 11, 2022	SELL	$5.86 - $13.23 $66,511 - $150,160	-11,350 Reduced 50.9%	10,949 $83,000
Q1 2022 May 12, 2022	SELL	$10.92 - $16.41 $37,237 - $55,958	-3,410 Reduced 13.26%	22,299 $290,000
Q4 2021 Feb 11, 2022	SELL	$15.81 - $18.99 $13 Million - $15.6 Million	-821,614 Reduced 96.97%	25,709 $432,000
Q3 2021 Nov 12, 2021	SELL	$12.68 - $17.79 $64,959 - $91,138	-5,123 Reduced 0.6%	847,323 $14.2 Million
Q2 2021 Aug 12, 2021	BUY	$12.95 - $15.41 $11 Million - $13.1 Million	852,446 New	852,446 $12.2 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $115M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.